(124)I-huA33 antibody PET of colorectal cancer.

Nuclear Medicine Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Journal of Nuclear Medicine (Impact Factor: 5.56). 08/2011; 52(8):1173-80. DOI: 10.2967/jnumed.110.086165
Source: PubMed

ABSTRACT Humanized A33 (huA33) is a promising monoclonal antibody that recognizes A33 antigen, which is present in more than 95% of colorectal cancers and in normal bowel. In this study, we took advantage of quantitative PET to evaluate (124)I huA33 targeting, biodistribution, and safety in patients with colorectal cancer. We also determined the biodistribution of (124)I-huA33 when a large dose of human intravenous IgG (IVIG) was administered to manipulate the Fc receptor or when (124)I-huA33 was given via hepatic arterial infusion (HAI).
We studied 25 patients with primary or metastatic colorectal cancer; 19 patients had surgical exploration or resection. Patients received a median of 343 MBq (44.4-396 MBq) and 10 mg of (124)I-huA33. Nineteen patients received the antibody intravenously and 6 patients via HAI, and 5 patients also received IVIG.
Ten of 12 primary tumors were visualized in 11 patients. The median concentration in primary colon tumors was 0.016% injected dose per gram, compared with 0.004% in normal colon. The PET-based median ratio of hepatic tumor uptake to normal-liver uptake was 3.9 (range, 1.8-22.2). Quantitation using PET, compared with well counting of serum and tissue, showed little difference. Prominent uptake in bowel hindered tumor identification in some patients. Pharmacokinetics showed that patients receiving IVIG had a significantly shorter serum half-time (41.6 ± 14.0 h) than those without (65.2 ± 9.8 h). There were no differences in clearance rates among the intravenous group, IVIG group, and HAI group, nor was there any difference in serum area under the curve, maximum serum concentration, or volume of distribution. Weak titers of human-antihuman antibodies were observed in 6 of 25 patients. No acute side effects or significant toxicities were associated with huA33.
Good localization of (124)I-huA33 in colorectal cancer with no significant toxicity has been observed. PET-derived (124)I concentrations agreed well with those obtained by well counting of surgically resected tissue and blood, confirming the quantitative accuracy of (124)I-huA33 PET. The HAI route had no advantage over the intravenous route. No clinically significant changes in blood clearance were induced by IVIG.

Download full-text


Available from: Achim A Jungbluth, Jun 22, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background:Colorectal cancer-specific biomarkers have been used as molecular targets for fluorescent intra-operative imaging, targeted PET/MRI, and selective cytotoxic drug delivery yet the selection of biomarkers used is rarely evidence-based. We evaluated sensitivities and specificites of four of the most commonly used markers: carcinoembryonic antigen (CEA), tumour-associated glycoprotein-72 (TAG-72), folate receptor-α (FRα) and endothelial growth factor receptor (EGFR).Methods:Marker expression was evaluated semi-quantitatively in matched mucosal and colorectal cancer tissues from 280 patients using immunohistochemistry (scores of 0-15). Matched positive and negative lymph nodes from 18 patients were also examined.Results:Markers were more highly expressed in tumour tissue than in matched normal tissue in 98.8%, 79.0%, 37.1% and 32.8% of cases for CEA, TAG-72, FRα and EGFR, respectively. Carcinoembryonic antigen showed the greatest differential expression, with tumours scoring a mean of 10.8 points higher than normal tissues (95% CI 10.31-11.21, P<0.001). Similarly, CEA showed the greatest differential expression between positive and negative lymph nodes. Receiver operating characteristic analyses showed CEA to have the best sensitivity (93.7%) and specificity (96.1%) for colorectal cancer detection.Conclusion:Carcinoembryonic antigen has the greatest potential to allow highly specific tumour imaging and drug delivery; future translational research should aim to exploit this.British Journal of Cancer advance online publication, 15 January 2013; doi:10.1038/bjc.2012.605
    British Journal of Cancer 01/2013; 108(3). DOI:10.1038/bjc.2012.605 · 4.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We describe an evaluation of the effect of the magnetic field on the PET spatial resolution and contrast recovery for short and long range positron emitters using experimental phantoms scanned on clinical PET/CT and PET/MR scanners as well as using electron transport simulations. A 22Na (a short range positron emitter) point source surrounded by Lucite, a 68Ga (a relatively long range positron emitter) line source surrounded by water, and a 68Ga contrast phantom with various sphere sizes were scanned on Siemens' Biograph-mMR (magnetic field strength: 3 Tesla) and Biograph-40 (no magnetic field). The electron transport simulations were performed from 0T to 11T for 22Na, 68Ga, and 15O for the point source, line source, and the contrast phantom. It was observed that the magnetic field has very small effect ( ) on the resolution of short range nuclides such as 22Na based on both simulation and experimental results as expected. For long range nuclides such as 68Ga slight improvements in spatial resolution and contrast recovery were observed on the plane perpendicular to the direction of the magnetic field from phantom experiments and simulations with 3T magnetic field for the human scanner. The degree of improvement is proportional to the positron range of the nuclides as well as the strength of the magnetic field, and it saturates at ~ 7T for all nuclides used in this study according to simulation results. For the plane parallel to the direction of the magnetic field, worse resolution and better contrast recovery were observed due to more positron annihilations deposited along the direction of the magnetic field (i.e. re-distribution of positrons). With regard to the results obtained from the simulations for a scanner with better intrinsic resolution (2 mm PSF), the improvement in FWHM saturates at a higher field strength ( ) as compared to that for a human scanner (4.7 mm PSF). Ho- ever, worse FWHM was observed in all directions at 3T as compared to that at 0T due to re-distribution of positrons and the interaction between the low frequency high energy positrons and the scanner's narrower intrinsic resolution kernel, while the FWTM and contrast recovery still improve at 3T. FWHM was observed to improve with higher magnetic field strength ( ). It was also found that the intrinsic resolution of the PET scanner needs to be worse/wider than 2.35 mm to observe an improvement in FWHM for a 68Ga point source in water under a 3T magnetic field as compared to that under 0T. In addition, a directionally dependent resolution modeling which accounts for the effect of the magnetic field in iterative PET reconstruction was observed to improve the resolution recovery and produce more uniform resolution in all directions within the magnetic field.
    IEEE Transactions on Nuclear Science 02/2015; 62(1):101-110. DOI:10.1109/TNS.2014.2373147 · 1.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The complementary nature of positron emission tomography (PET) and optical imaging (OI) has fueled increasing interest in the development of multimodal PET/OI probes that can be employed during the diagnosis, staging, and surgical treatment of cancer. Due to their high selectivity and affinity, antibodies have emerged as promising platforms for the development of hybrid PET/OI agents. However, the lack of specificity of many bioconjugation reactions can threaten immunoreactivity and lead to poorly-defined constructs. To circumvent this issue, we have developed a chemoenzymatic strategy for the construction of multimodal PET/OI immunconjugates that have been site-specifically labeled on the heavy chain glycans. The methodology consists of four steps: (1) the enzymatic removal of the terminal galactose residues on the heavy chain glycans; (2) the enzymatic incorporation of azide-bearing galactose (GalNAz) residues into the heavy chain glycans; (3) the strain-promoted click conjugation of chelator- and fluorophore-modified dibenzocyclooctynes to the azide-modified sugars; and (4) the radiolabeling of the immunoconjugate. For proof-of-concept, a model system was created using the colorectal cancer-targeting antibody huA33, the chelator desferrioxamine (DFO), the positron-emitting radiometal (89)Zr, and the near-infrared fluorescent dye Alexa Fluor(®) 680. The bioconjugation strategy is robust and reproducible, reliably producing well-defined and immunoreactive conjugates labeled with 89Zr, Alexa Fluor® 680, or an easily and precisely tuned mixture of the two reporters. In in vivo PET and fluorescence imaging experiments, a hybrid (89)Zr- and Alexa Fluor(®) 680-labeled huA33 conjugate displayed high levels of specific uptake (>45% ID/g) in athymic nude mice bearing A33 antigen-expressing SW1222 colorectal cancer xenografts.
    Bioconjugate Chemistry 11/2014; 25(12). DOI:10.1021/bc500499h · 4.82 Impact Factor